$37 Million is the total value of Ulys, L.L.C.'s 1 reported holdings in Q1 2018. The portfolio turnover from Q4 2017 to Q1 2018 was 0.0% .
| Value | Shares | ↓ Weighting | ||||||
|---|---|---|---|---|---|---|---|---|
| LXRX | LEXICON PHARMACEUTICALS INC | $37,033,000 | -13.3% | 4,321,214 | 0.0% | 100.00% | 0.0% |
Original filings
The following EDGAR filing(s) were analyzed to create this report:
- View 13F-HR filed 2018-05-10
Top long-term holdings
| Name | Quarters owned | Latest quarter owned | Max weighting |
|---|---|---|---|
| LEXICON PHARMACEUTICALS INC | 24 | Q1 2021 | 100.0% |
| LEXICON PHARMACEUTICALS INC | 8 | Q1 2015 | 100.0% |
| CERES INC | 8 | Q1 2015 | 0.2% |
| CERES INC | 5 | Q2 2016 | 0.0% |
View Ulys, L.L.C.'s complete holdings history.
Latest filings
| Type | Filed |
|---|---|
| 4 | 2022-08-09 |
| 4 | 2022-08-01 |
| 13F-HR | 2021-05-14 |
| 13F-HR | 2021-02-11 |
| 13F-HR | 2020-11-13 |
| 13F-HR | 2020-08-14 |
| 13F-HR | 2020-05-14 |
| 13F-HR | 2020-02-13 |
| 13F-HR | 2019-11-14 |
| 13F-HR | 2019-08-09 |
View Ulys, L.L.C.'s complete filings history.
All filings
- Holdings (13F-HR)
- Significant ownership (13-D/G)
- Insider transactions (4, 5, 6)
- Events (8-K)
- Shareholder votes (proxy)
View complete filings history.